As generative AI moves toward performing increasingly consequential clinical functions, the American Medical Association (AMA) is urging the U.S. Food and Drug Administration to address a foundational ...
Rick Abramson, a radiologist by training and the director of FDA's Digital Health Center of Excellence said, "We ended up ...
The GSK cancer immunotherapy Jemperli is now approved for treating advanced cases of rectal cancer harboring a particular ...
A new report on third quarter M&A activity in the healthcare sector found that this quarter’s hospital and health system ...
City Therapeutics’ lead RNA interference therapy could become an alternative to blockbuster-selling anticoagulants. The ...
OMass’s molecule is vying to become an alternative to a Neurocrine Biosciences drug that is currently the only FDA-approved ...
Cell and gene therapies are amazing medical breakthroughs but if we don’t find ways to pay for them, the development pipeline ...
The Silence Therapeutics acquisition gives Merck KGaA a drug ready for a pivotal test in the blood disorder polycythemia vera ...
Some of the thorniest problems in medicine that AI can improve have nothing to do with diagnosis. They have to do with triage ...
This is not a discovery problem. It is a market entry and access problem, and it is far more tractable than the pipeline ...
Iambic Therapeutics, an AI-enabled biotech company, will apply the IPO proceeds toward clinical development of its pipeline ...
AdvaMed CEO Scott Whitaker outlined four policy priorities at the MedTech Conference: tariffs, FDA user fees, payment and coverage, and cybersecurity.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results